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Abstract. Poly(MePEG2000cyanoacrylate-co-hexadecylcy-
anoacrylate) (PEG-PHDCA) nanoparticles have demon-
strated their capacity to reach the rat central nervous
system after intravenous injection. For insight into the
transport of colloidal systems across the blood-brain bar-
rier (BBB), we developed a relevant in vitro rat BBB
model consisting of a coculture of rat brain endothelial
cells (RBECs) and rat astrocytes. The RBECs used in our
model displayed and retained structural characteristics of
brain endothelial cells, such as expression of P-glyco-
protein, occludin and ZO-1, and immunofluorescence
studies showed the specific localization of occludin and
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ZO1. The high values of transendothelial electrical resis-
tance and low permeability coefficients of marker mole-
cules demonstrated the functionality of this model. The
comparative passage of polyhexadecylcyanoacrylate and
PEG-PHDCA nanoparticles through this model was in-
vestigated, showing a higher passage of PEGylated
nanoparticles, presumably by endocytosis. This result
was confirmed by confocal microscopy. Thanks to a good
in vitro/in vivo correlation, this rat BBB model will help
in understanding the mechanisms of nanoparticle translo-
cation and in designing new types of colloidal carriers as
brain delivery systems.
Key words. Rat blood-brain barrier in vitro model; brain endothelial cell; tight junction; PEGylated-nanoparticle;
transport of nanoparticle.
Drug delivery to the brain is a challenge, because this
tissue benefits from very efficient protection. The same
mechanisms that protect the brain from foreign substances
also restrict the entry of many potentially therapeutic
agents. Thus, numerous new chemical entities for treating
brain disorders are not clinically useful due to the presence
of the blood-brain barrier (BBB). To increase the bio-
availability of these molecules, nanoparticles can now be
* Corresponding author.
used to deliver them to the brain [1]. In general, drugs can
be dissolved, entrapped, encapsulated or attached to a
nanoparticle matrix, serving as ‘trojan horses’ for a wide
variety of new chemical entities. In such a manner, drug
loading onto nanoparticles has been found by many au-
thors [2–4] to modify the cell and tissue distribution. This
may lead to a more selective delivery of biologically active
compounds to improve drug efficacy and reduce the drug
toxicity. In this context, Kreuter’s group has developed
poly(butylcyanoacrylate) (PBCA) nanoparticles onto the
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surface of which the desired drug was adsorbed and then
overcoated with polysorbate 80 (PS-80). These nanopar-
ticles have been used as a vector for the brain delivery of
dalargin [5], loperamide [6] and doxorubicin [7]. However,
recently, Olivier et al. [8] suggested that the PBCA
nanoparticles coated with PS-80 displayed some toxic
effect towards the BBB by opening the tight junctions
between endothelial cells in the brain microvasculature,
thus creating a paracellular pathway for nanoparticle
translocation. This toxicity, which was not observed in
either the in vitro or in vivo studies performed by Kreuter
et al. [9], could be due to the desorption processes of
PS-80. This process, in addition to the drug desorption,
could explain the efficacy loss of dalargin adsorbed onto
PS-80 nanoparticles 5 min after intravenous (IV) injection
[10]. One emerging strategy to avoid the desorption
process is the formation of nanoparticles from an am-
phiphilic copolymer in which the hydrophobic block itself
is able to form a solid phase where hydrophobic drugs can
be encapsulated, while the hydrophilic block remains as a
surface-exposed cloud (core-shell nanoparticles). In fact,
when decorated with hydrophilic polymers such as poly-
ethylene glycol (PEG), nanoparticles are protected by a
steric barrier against interactions with plasma proteins,
resulting in a longer circulation time in the blood com-
partment [11, 12]. This prolongation of the half-life in
plasma will increase the chances of nanoparticles reach-
ing the central nervous system (CNS) where the bio-
degradation of the nanoparticles would allow a pro-
longed leakage of the drug. More surprisingly, in vivo
studies have also shown that poly(MePEG2000cyanoacry-
late-co-hexadecylcyanoacrylate (PEG-PHDCA) nanopar-
ticles which have a shorter plasma half-life than other
long-circulating carriers were also able to penetrate the
CNS of normal rats when the BBB was intact, to a signif-
icantly higher degree than the other systems [13]. These
results have suggested that the mechanism of nanoparticle
translocation through the BBB is influenced by interac-
tions between brain endothelial cells and nanoparticles
with a specific surface composition. From this perspective,
the development of a relevant rat BBB model was of
primary importance for  understanding the mechanism
underlying nanoparticle translocation. 
Many protocols have been reported for the culture of
brain endothelial cells. These techniques generally employ
large animals, such as bovine or porcine species which
offer obvious advantages in terms of starting material
[14–17]. However, since in vivo experimental models of
CNS diseases are generally effected in the rat, in vitro
models of the BBB with bovine endothelial cells may be
inappropriate for investigating the mechanism of nano-
particle translocation, especially when blood protein ad-
sorption and opsonization may be involved. Rodent brain
endothelial cells in culture present rapid dedifferentiation
and a loss of their specific characteristics [18]. Some in
vitro cultures of rat endothelial cells have been developed
[19, 20], but no model is well established. Therefore, in-
vestigation of nanoparticle translocation required the de-
velopment of a relevant and well characterized rat model
of the BBB where the most important in vivo character-
istics of the BBB such as tight junction (TJ) localization, P-
glycoprotein (P-gp) expression and permeability coeffi-
cient (Pe) could be investigated. The purpose of this study
was to establish an in vitro rat model of the BBB based 
on a coculture, to evaluate colloidal-drug-carrier translo-
cation.
Materials and methods 
Cell isolation and culture 
All protocols involving animals comply with European
Community guidelines for the care and use of laboratory
animals (Directive n°. 86/609 CEE). 
Rat brain capillaries
These were isolated using the procedure of Szabo et al.
[19] modified as described. Brain cortex from 2-week-old
Sprague-Dawley rats (Charles River Laboratories,
L’Arbresle, France) was used after elimination of meninges
and grey matter. Tissues were digested at 37 °C in col-
lagenase-dispase solution for 1 h 30 min (Boehringer,
Mannheim, Germany). Cold DMEM-F12 (Invitrogen,
Cergy Pontoise, France) was added to the homogenate
and centrifuged at 1000 g, 4°C for 5 min. The pellet was
resuspended in 25% Bovine serum albumin (BSA)
(Sigma-Aldrich, St. Louis, Mo.) and centrifuged at 1500 g,
4°C for 15 min. The resulting pellet was then digested at
37°C for 1 h in enzymatic solution as above. This new
digest was filtered through a 10-mm-pore-size nylon mesh
and washed three times with DMEM-F12. Finally, the
nylon mesh was recovered and the capillary fragments
were washed off the mesh by propulsion of culture
medium EBM-2 containing 10% fetal bovine serum
(FBS), antibiotic cocktail (Cambrex, Verviers, Belgium)
and 3 mg/ml puromycin (Sigma-Aldrich). Briefly, this
treatment with 3 mg/ml puromycin for 3 days after brain
capillary isolation eradicates almost all the contaminating
cells because puromycin is cytotoxic for cells lacking P-gp.
Rat brain endothelial cells (RBECs) express a high level
of P-gp which prevents intracellular accumulation of
puromycin and cytotoxicity. Puromycin allows the pro-
liferation of only RBECs (98–99% purity) with the
characteristic shape and a high level of transendothe-
lial electrical resistance of the monolayer formed [18]. 
The capillary fragments were seeded on collagen S
(Boehringer) coated plastic dishes 60 mm in diameter
(Corning Costar, Cambridge, Mass.) and incubated in a
water-saturated atmosphere of air and 5% CO2 at 37°C.
After 3 days, culture medium was replaced, puromycin
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was removed from the culture medium and EBM-2 MV
singlequots (Cambrex) were added. To confirm the purity
of RBECs, the expression of a specific endothelial cell
marker (von Willebrand factor) was identified. Five-day-
old cultures were fixed at room temperature in PBS 
containing 1% paraformaldehyde (20 min) and incubated
with the rabbit polyclonal anti-human von Willebrand
factor antibody (DAKO; 1:50 dilution, 10 min). Cells
were then stained according to the protocol of the DAKO
(Trappes, France) LSAB2 Kit, Peroxidase for use on rat
specimens (Universal K609). 
Astrocytes
These cells were isolated from brain cortex of Sprague-
Dawley rats 1–3 days after birth. After elimination of
meninges, the cortex was disaggregated through a 10-ml
pipette in 4¥10–3mol/-EDTA (Invitrogen) in Ca2+/Mg2+
free PBS for 10 min at room temperature. The homoge-
nized tissue was filtered through an 80-mm filter. The
remaining cells were directly plated on 75-cm2 culture
flasks in DMEM/F12 medium containing 20% FBS and
antibiotics (penicillin 100 U/ml, streptomycin 100 mg/ml).
The medium was changed every 3 days. After 7 days, the
flasks were shaken at 37°C for 24 h in order to eliminate
the contaminating microglia. Subsequently, the astrocytes
were transferred at first passage to the bottom of the
12-well plates at a concentration of 50,000cells/cm2 to
form the in vitro model. As with RBECs, the expression
of a relatively specific astrocyte cell marker (glial fibrillary
acidic protein, GFAP) was determined according to the
same protocol.
Characterization of the in vitro BBB model 
RBECs at first passage were cultured on type-IV-collagen-
coated Transwells (3.0 mm pore size, 1 cm2 growth area;
Corning Costar) at a density of 100,000 cells/cm2. The
Transwells were placed into 12-well plates containing
astrocytes cultures. The coculture medium was EBM-2
MV, supplemented with 5% (v/v) FBS and singlequots.
Immunofluorescence
RBECs and human umbilical vascular endothelial cells
(HUVECs) were fixed in PBS containing 1% para-
formaldehyde (20 min) and then permeabilized (15 min
with 0.1% Triton X-100 in PBS). Cells were exposed to
1% FBS for 30 min to block non-specific binding sites.
Polyclonal rabbit anti- ZO-1 or anti-occludin (Zymed, San
Francisco, Calif.) was applied overnight in a humidified
atmosphere and the cells were then washed three times
with PBS. The secondary antibody [FITC-conjugated
goat anti-rabbit IgG (Zymed)] was applied for 1 h, after
which cells were washed five times. Rhodamine-conju-
gated phalloidin (Sigma-Aldrich) was applied for 15 min,
followed by three washes with PBS. Three different con-
trols were performed for each labeling experiment: (i)
specific antibody controls, (ii) incubation with only the
secondary-labeled antibodies, and (iii) estimation of aut-
ofluorescence of unlabeled cells.
Stained specimens were viewed with an LSM 510 Zeiss
confocal inverted microscope equipped with a Zeiss
¥63/1.4 NA oil immersion objective lens. Fluorescence
images were acquired with argon (wavelength 488 nm)
and helium neon (wavelength 543 nm) lasers.
Western blot analysis
Western blot was used to determine P-gp, occludin and
ZO-1 expression. Briefly, cells were scraped from the bot-
tom of the filter insert and solubilized with lysis buffer
(10 mM Tris pH 7.5, 5 mM EDTA, 125 mM NaCl, 1%
Triton, 0.1% SDS and protease inhibitor cocktail; Sigma-
Aldrich). The protein concentration was determined using
the colorimetric Bicinchoninic Assay Kit (Uptima, Inter-
chim, Montlucon, France) with BSA as standard. Five
micrograms of cellular proteins was subjected to SDS-
polyacrylamide gel electrophoresis with 8% polyacry-
lamide and transferred onto a nitrocellulose membrane
which was then incubated with primary antibody [C219
(DAKO), anti-ZO-1, anti-occludin, diluted 1:100], followed
by a peroxidase-conjugated anti-rabbit IgG as secondary
antibody (DAKO). The immunoreactive bands were 
visualized with an enhanced chemiluminescent system
(Amersham Biosciences, Saday, France). 
Transendothelial electrical resistance
Transendothelial electrical resistance (TEER) of RBEC
monolayers in the presence or absence of astrocytes was
measured with an ENDOHM tissue resistance measure-
ment chamber (World Precision Instruments, Sarasota,
Fla.). The average of values corresponding to five coated
Transwells (without cells) was subtracted from the 
resistance of transwells with RBECs to give the resistance
of the cell monolayer. The results were expressed in
Ωcm2.
Permeability studies 
Cell layer permeability was determined concurrently
with the serial measurements of TEER. The paracellular
permeability across RBEC monolayers was measured
using [14C]sucrose (0.5 mCi/ml) and [3H]inulin (1 mCi/ml;
Amersham) as hydrophilic markers. Permeability studies
were undertaken at 37°C in permeation medium (EGM-2
MV medium with 5% FBS). At selected times points of
20, 40, 60, 120, 180 and 240 min after the addition of the
sucrose/inulin solution in the upper compartment, the
inserts were subsequently transferred to other wells to
minimize back diffusion of compound to the upper com-
partment. At the end of the experiments, for each time
point, aliquots were taken from the lower compartments,
and radioactivity was determined (BECKMAN model LS
6000TA). Permeabilities of RBECs were calculated 
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according to the method of Siflinger-Birnboim et al. [21]
using the clearance principle as described previously
[22]. All experiments were repeated at least ten times.
Biodegradable cyanoacrylate nanoparticle
preparation and characterization
[14C]radiolabeled nanoparticles were prepared with either
poly(hexadecylcyanoacrylate) ([14C](PHDCA) or [14C]
PEG-PHDCA. These polymers were prepared at the
Commissariat à l’Energie Atomique (Saclay, France)
according to previously described protocols [11, 23].
[14C]PHDCA and [14C]PEG-PHDCA had a specific 
activity of 5.8 and 1.5 mCi/mg, respectively. Biodegradable
[14C]PHDCA and [14C]PEG-PHDCA nanoparticles were
obtained and characterized by the methods previously
described [24]. Nanoparticle degradation products were
also obtained as previously described [25]. Fluorescent
nanoparticles were prepared with the same method 
except that non-radiolabeled polymers were used and nile
red (Interchim, Montluçon, France), a fluorescent marker
(25 mg), was added. 
Translocation of nanoparticles and [14C]PEG-PHDCA
nanoparticle degradation products across the in vitro
BBB model
Experiments were initially conducted to determine the
ability of nanoparticles to cross the RBEC monolayer.
This was accomplished at 37°C at a concentration of 
20 mg/ml of boths nanoparticle types between 13 and 17
days in coculture and monoculture. Translocation experi-
ments were conducted from the upper to lower compart-
ments with sampling time points of 20, 40, 60, 120, 180
and 240 min, and [3H]inulin was used to verify in vitro
BBB model integrity. Free transport of nanoparticles
through the coated Transwell lacking RBECs was
checked. For each time point, aliquots were taken from
the lower compartments, and radioactivity was deter-
mined. Studies were also undertaken with degraded
[14C]PEG-PHDCA nanoparticles. 
RBEC uptake of nanoparticles
To determine nanoparticle uptake, RBECs were then
incubated with a suspension of fluorescent nanoparticles
(20 mg/ml) in permeation medium for 1 h at 37°C. At the
end of incubation, the cell monolayers were rinsed three
times with PBS to remove excess nanoparticles. Cell
monolayers were then fixed with paraformaldehyde (1%)
in PBS for 15 min and samples were analyzed with a
confocal microscope.
Statistical analysis
All data are expressed as means (n=6) ± SE. Sets of data
were compared using the non-parametric Mann-Whitney
test. Differences were considered significant at p<0.05.
The reproducibility of our model was statistically analyzed
with ten independent cocultures using the TEER values
(n = 5) and the permeability coefficients for sucrose and
inulin (n = 5). 
Results
Assessment of the rat BBB model
We succeeded in routinely obtaining RBEC cultures with
98% purity as demonstrated by granular cytoplasmic
staining for von Willebrand Factor, a specific marker of
endothelial cells (fig. 1a). The purity of astrocyte cultures,
which do not form a monolayer, was also checked by
labeling cells with GFAP antibody (fig. 1b). Because this
marker is not specific for astrocytes but is also present in
glial cells, the identification of astrocytes was confirmed
by morphology observation (fig. 1b) as in previous studies
[18]. 
The in vitro BBB model was realized in a Transwell system
using RBECs on one side of a polyester filter and rat
astrocytes in the bottom well. It was characterized by
analysis of the expression and localization of proteins
which are specific to brain endothelial cells and by mea-
surements of transendothelial electrical resistance and
permeability to small molecules. 
The expression in RBECs of specific proteins, like P-gp
and two proteins incorporated into TJs, occludin and ZO-1,
was detected by immunoblotting studies. Western blots
revealed the presence of theses proteins: P-gp was detected
as a specific band of 170 kDa, occludin as a band migrating
at 60 kDa, and ZO-1 protein at 225 kDa (fig 2a).
The localization of the transmembrane protein, occludin,
and of the cytoplasmic protein, ZO-1, in RBECs in cocul-
Figure 1. Characteristics of cultured rat brain endothelial cells (a)
and astrocytes (b) by phase-contrast microscopy and immunocyto-
chemistry labeling: (1) unlabeled cells, (2) labeled cells with no
specific primary antibodies, (3) labeled cells with specific primary
antibodies–von Willebrand factor in cultured RBECs (a3) and
GFAP in astrocytes (b3).
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ture with astrocytes, was performed by confocal micros-
copy (fig. 2b). Cultured RBECs clearly expressed occludin
in a continuous cell-to-cell contact. The distribution of
ZO-1 in RBECs appeared as continuous lines at the cell
borders. Since actin filaments also play an important
role in the organization of TJs, actin was stained with
rhodamine-phalloidin. Actin filaments were predominantly
found at the circumference of endothelial cells. In contrast,
cultures of HUVECs, which are endothelial cells of non-
cerebral origin, displayed lower levels and a diffuse local-
ization of occludin, ZO-1 and F-actin, suggesting a low
degree of junctional tightness (fig. 2c). 
The characterization of the in vitro BBB model was com-
pleted by measuring electrical resistance. RBECs in mono-
culture and coculture with astrocytes displayed TEER
values increasing daily until 13 days after confluence
without significant differences between the two systems.
Of note is that, as shown in figure 3a, cocultures con-
served high TEER values until 25 days, while RBEC
monolayers (in monoculture) showed a significant de-
crease (fig. 3). Occludin expression was also studied as a
function of culture time by Western blotting; it showed a
decrease of expression after 28 days in both cases, but
this decrease was more significant for the monolayer sys-
tem (fig. 3b). Both these observations suggest a loss of
integrity of the RBEC monolayer in the absence of co-
culture with astrocytes.
The functionality of our BBB model was confirmed by
measuring the permeability coefficients of sucrose and
inulin. Indeed, the very low paracellular Pe values of
[14C]sucrose (1.86 ¥ ± 0.18 ¥ 10–6cm/s) and [3H]inulin
(1.38 ¥ ± 0.36 ¥ 10–6cm/s) verified the establishment of
an impermeable barrier. In addition, the statistical analysis
demonstrated the reproducibility of our model in terms of
TEER values and the permeability coefficients (p<0.05). 
Nanoparticle translocation
The newly established BBB model was used to investigate
the translocation and uptake of PHDCA and PEG-PHDCA
nanoparticles. The characteristics of PHDCA and PEG-
PHDCA nanoparticles were not significantly different in
terms of size (166 and 171 nm, respectively). Both kinds
Figure 2. a Western blot analysis of occludin, ZO-1 and P-gp in
RBECs after 13 days in a coculture system. (b, c) Confocal mi-
croscopy of the distribution of occludin, ZO-1 and F-actin in
RBECs (b) and HUVEC (c) after 13 days in coculture. F-actin was
stained with rhodamine-phalloidin. Bar, 10 mm. 
Figure 3. a TEER of endothelial cell monolayers in monoculture
(closed circles) and coculture with astrocytes (open circles) for 3
weeks after plating onto a collagen-coated filter insert. All data are
expressed as the means (n=15) ± SE. b. Western Blot analysis of 
occludin in RBECs in the coculture system at 13 days (lane 1), and
at 28 days (lane 2); monoculture system at 13 days (lane 3) and at
28 days (lane 4).
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of nanoparticle freely diffused through the coated filter in
the absence of cells (fig. 4a). During the incubation period,
the translocation of PEG-PHDCA nanoparticles across
RBECs was greater than that of PHDCA nanoparticles
(fig. 4b). The same results were obtained between 13 and
17 days in monoculture, as expected (data not shown).
To answer the question if the radiolabeled compounds
diffused through the rat BBB model as intact nanoparticles
or as their already metabolized products, we performed
additional experiments with pre-degraded nanoparticles.
Nanoparticle degradation products were unable to diffuse
as soluble compounds through the in vitro BBB model
(fig. 4b). Moreover, we confirmed the uptake of fluorescent
nanoparticles by incubating nanoparticles loaded with
nile red with RBECs for 1 h. The images obtained by con-
focal microscopy demonstrated lower uptake of PHDCA
nanoparticles by RBECs (fig. 5a) in comparison with
PEG-PHDCA nanoparticles (fig. 5b). The cell uptake of
PEG-PHDCA nanoparticles was seen as highly fluorescent
punctuated patterns, preferentially located in the cytoplasm
or around the nucleus. 
To determine whether the passage of PEG-PHDCA
nanoparticles was due to a modification in the TJs, the
permeability coefficients for [3H]inulin were determined
in the presence and in the absence of these nanoparticles.
Since the Pe values were similar in the presence and
absence of nanoparticles (1.62 ± 0.32 ¥ 10–6 cm/s and
1.67 ± 0.04 ¥ 10–6 cm/s, respectively), we concluded that
RBEC monolayer integrity was maintained in the pres-
ence of nanoparticles. In addition, the TEER values of
cocultures, during 5 h of incubation with PEG-PHDCA
or PHDCA nanoparticles, were also not significantly
different compared to those of cocultures without
nanoparticle incubation (fig. 6). These results confirm
the absence of modification of the TJs by the nano-
particles.
Figure 5. Confocal microscopic images of uptake of fluorescent
nanoparticles composed of PHDCA (a) and PEG-PHDCA (b) by
rat brain endothelial cells (13 days of culture) after 1 h of incubation.
Figure 6. TEER values of cocultures (13 days of culture) without 
incubation of nanoparticles (open bars), with incubation of PEG-
PHDCA nanoparticles (closed bars) or with incubation of PHDCA
nanoparticles (hatched bars). All data are expressed as the means
(n=10) ± SE.
Figure 4. Translocation of radiolabeled PHDCA nanoparticles
(open triangles), PEG-PHDCA nanoparticles (closed triangles) and
degraded PEG-PHDCA nanoparticles (open squares) across cell-
free collagen-coated filter inserts (a) and across RBECs after 13
days in coculture with astrocytes (b).
a b
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Discussion
To assess nanoparticles transport through the BBB, we
developed a syngenic in vitro BBB coculture model using
RBECs and astrocytes from the same species. 
The method for isolating RBECs and the use of a
puromycin treatment [18] allowed high cellular density
from the beginning of the culture, fast proliferation and
confluence. These conditions were favorable for excluding
contaminating cells which, because of their low percent-
age, had no opportunity to proliferate (fig. 1). The cell pu-
rity obtained in these experiments was confirmed by the
high electrical resistance values (fig. 3).
One of the major problems of in vitro studies is the loss
of BBB properties. However, Western blot analysis has
demonstrated the expression of P-gp which is character-
istic of endothelial cells in the brain tissue [26]. Another
point to consider is the presence of efficient TJs between
RBECs as confirmed by Western blotting and confocal
microscopy (fig. 2). Confocal microscopy studies showed
the presence of occludin (a transmembrane protein) and
ZO-1 (a cytoplasmic protein) which are important compo-
nents of TJs. The role of the N-terminal half of occludin
in TJ assembly is presumed to be maintenance of the
barrier function of these junctions. On the other hand,
ZO-1 is bound to actin filaments and the C-terminus of
occludin [27], and the structural organization of actin has
been shown to influence TJ integrity [28]. The choice of
these marker proteins was also justified by the fact that
occludin is a well-known regulatory protein, and its
presence at the BBB is correlated with increased electrical
resistance across the barrier and decreased paracellular
permeability [29]. Our results confirm this correlation
because at 25 days of monoculture, we observed in
RBECs decreases of both occludin expression and TEER
values (fig. 3). 
Additionally, maximum TEER values obtained after 13
days (220–300 Ωcm2) were higher than the values re-
ported for a coculture system of bovine brain endothe-
lial cells and rat astrocytes at the bottom of the well,
(134 Wcm2) [17]. At the beginning, no significant dif-
ferences in TEER values were observed between the
monoculture and coculture, showing that RBECs pre-
served BBB properties after isolation (fig. 3a). How-
ever, astrocytes were needed to maintain transendothe-
lial electrical resistance over a period of 25 days in co-
culture. Several other in vitro BBB models [16, 30–32]
employing brain endothelial cells after diverse subcul-
tures have shown a dedifferentiation and loss of BBB
properties. Thus, astrocytes have a remarkable influence
in inducing and maintaining BBB properties, as con-
firmed by our results for a long period of coculture
(fig. 3). Considering that RBECs could lose characteris-
tics other than TJ functionality, which might also be im-
portant for nanoparticle translocation, we chose to build
this in vitro BBB model with coculture system between
RBEC and astrocytes.
The low paracellular permeability is also an indication
that cultured brain endothelial cells possess junctional
complexes [33]. Hence the functionality of these tight
junction complexes was tested through permeability
studies using radiolabeled substances such as sucrose and
inulin which are impermeable markers of TJs, not taken up
by the endothelial cells in vivo either by active facilitated
transport. The Pes for sucrose and inulin (average molecu-
lar weight about 342 and 5000, respectively) through
RBECs were in the order of 1.72 ± 0.02 ¥ 10–6 cm/s and
1.28 ± 0.01 ¥ 10–6 cm/s, respectively. These Pe data were
similar to the values previously reported [34] in porcine
brain capillary endothelial cells (1.0 ± 0.4 ¥ 10–6 cm/s for
sucrose and 1.0 ± 0.3 ¥ 10–6 cm/s for inulin) with TEER
values of 600 Ωcm2, four times lower, for sucrose, than
the values (8.0 ¥ 10–6 cm/s) obtained by Lundquist et al.
[35] in a coculture of bovine brain endothelial cells and
rat astrocytes (TEER = 800 Ωcm2). These observations
demonstrated that models with high TEER values do not
necessarily show good BBB properties such as paracellular
impermeability. Taken together, our data show that in the
presence of rat astrocytes, RBECs formed, in our experi-
mental conditions, a model with properties close to the in
vivo situation. Other in vitro cultures of RBECs have
been developed but no evaluation of the critical properties
of the BBB was reported in these studies [19, 20, 36].
Thus, this model displayed characteristics and function-
ality consistent with the in vivo BBB and was found to be
consistently reproducible enough for further investigation,
as our studies on nanoparticle translocation across the
BBB.
PEG-PHDCA nanoparticles showed a three fold greater
crossing of the experimental BBB than PHDCA nanopar-
ticles (4 h incubation), clearly demonstrating that the nano-
particle surface (presence of hydrophilic and flexible PEG
chains) is a key parameter for intracellular uptake (fig. 4).
These data correlated very well with those previously
obtained in vivo after intravenous administration to the
rat of PEG-PHDCA nanoparticles which concentrated
more than PHDCA nanoparticles in the different brain
structures [13, 24]. Thanks to the development of this rat
BBB model, we have established a good in vitro/in vivo
correlation and the cellular mechanisms implicated in the
translocation of PEG-PHDCA and PHDCA nanoparticles
through the BBB may be further investigated.
Particle surface properties are likely to play an important
role in the translocation process. Both types of nanopar-
ticle had the same size, but only nanoparticles decorated
with PEG were able to cross the in vitro model of BBB.
Moreover, in previous studies, the increased in vivo brain
penetration of PEG-PHDCA nanoparticles was achieved
without modification of BBB permeability, as determined
by a sucrose assay [24]. Using the in vitro model of the
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BBB developed here, we confirmed the absence of TJ
modification, since TEER measurements and inulin assays
showed that the increased translocation of PEG-PHDCA
nanoparticles did not result from a single paracellular
diffusion due to a disruption of the RBEC monolayers
(fig. 6). 
Nanoparticle degradation products which are constituted
in major part by the hydrophilic and water-soluble
poly(cyanoacrylic acid) [37, 38] did not diffuse through
the cell layers (fig. 4b). The results presented here suggest
that intact PEG-PHDCA nanoparticles were transported
across the in vitro BBB, likely through an endocytotic
process, which was also confirmed by confocal micros-
copy images (fig. 5). 
For further study of nanoparticle translocation, an RBEC
fractionation method was also developed recently [39]
and showed accumulation of PEG-PHDCA nanoparticles
in intracellular compartments of vesicles. On the other
hand, previous studies have suggested that the mechanism
for nanoparticle delivery across the BBB is most likely
related to endocytosis via the low-density lipoprotein
(LDL) receptor in endothelial cells that form the BBB
[40]. This endocytotic uptake seems to be mediated by the
adsorption of apolipoprotein B and/or E on nanoparticles
from the blood. Thus, the nanoparticles could mimic
lipoprotein particles and act as ‘trojan horses’. In fact,
Peracchia et al. [12] have observed the adsorption of
apolipoprotein E onto the surface of PEG-PHDCA nano-
particles, after incubation with human citrate-stabilized
plasma. Interestingly, the images of the intracellular local-
ization of PEG-PHDCA nanoparticles (fig. 5) are similar
to those of a transcellular transport as described for 
LDL [41].
Further experiments using this newly developed in vitro
BBB model of the rat and cultures of pure RBECs are 
in progress to study this hypothesis of LDL-receptor-
mediated endocytosis and to elucidate the pathways of
nanoparticle transport.
In conclusion, this study describes an original and repro-
ducible in vitro model of the rat BBB which presents the
main morphological and functional characteristics of the
BBB in vivo. Using polyalkylcyanoacrylate nanoparticles,
such a model was shown to be relevant in terms of in
vitro/in vivo correlations. This methodology should be a
useful tool for the design of new colloidal carriers with
the aim of brain drug delivery.
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